Lannett (LCI) – Lawsuits Will Wipe Out The Equity" Citron ResearchGuest Post
If Even Modest Price Cuts Hit Either of Lannett’s Cash Cow Drugs, It Will Violate Its Debt Covenants
$13-$15 Near Term Target
Equity Worthless Over Long-Term
Over the past year, almost every media outlet in the US has dissected the pharmaceutical industry to expose the culprits of rampant opportunistically driven price gouging. We are . . .
This content is exclusively for paying members. Sign up here
If you are subscribed and having an account error please clear cache and cookies if that does not work email email@example.com or click chat